Evaluation of antipruritic effects of serlopitant, a neurokinin 1 receptor antagonist, in patients with epidermolysis bullosa: A phase 2 randomized controlled trial.
J Eur Acad Dermatol Venereol
; 2024 Jul 01.
Article
in En
| MEDLINE
| ID: mdl-38949042
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
J Eur Acad Dermatol Venereol
Journal subject:
DERMATOLOGIA
/
DOENCAS SEXUALMENTE TRANSMISSIVEIS
Year:
2024
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom